JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Retrospective analysis of glial tumors in light of the 2016 WHO classification of central nervous system tumours diagnosed at a single center between 2005 and 2016
Abstract
Aims: The 2016 WHO Classification of Tumors of the Central Nervous System introduced a paradigm shift by integrating molecular features with traditional histomorphology. This study aims to retrospectively re-evaluate glial tumor cases from a major tertiary center in light of these evolving classification criteria and provide a baseline for future molecular research.
Methods: A retrospective analysis was conducted on 395 glial tumor cases diagnosed at the Karadeniz Technical University Faculty of Medicine, Department of Pathology, between 2005 and 2016. The cases were re-grouped according to the 2016 WHO criteria. Due to the lack of molecular data available during the archival period, cases were categorized under the “Not Otherwise Specified” (NOS) group to establish a comprehensive database.
Results: Among the 395 cases analyzed, glioblastoma was identified as the most frequent histological subtype (n=235). A male predominance was observed (56.5%), with mean and median ages of 48.21 and 50 years, respectively. The most common anatomical location was the frontal lobe, and Histological Grade IV was the most prevalent grade. Statistical analyses indicated that demographic and distribution data were consistent with global literature.
Conclusion: The findings align with international demographic trends while highlighting the practical challenges of transitioning to molecular-based classifications. While the subsequent 2021 WHO Classification further emphasizes IDH status, "histologically defined" or "NOS" designations remain crucial for regions where molecular testing infrastructure is limited. This study provides a robust archival baseline that facilitates future molecular studies and serves as a reference for glial tumor characterization in resource-constrained settings.

Keywords : Central nervous system, 2016 WHO classification, glial tumors

Download Article


1. Brunetti A, Alfano B, Soricelli A, et al. Functional characterization of brain tumors: an overview of the potential clinical value. Nucl Med Biol. 1996;23(6):699-715. doi:10.1016/0969-8051(96)00069-8
2. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18:v1-v75. doi:10. 1093/neuonc/now207
3. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro Oncol. 2017;19(11):1553-1564. doi:10.1093/neuonc/nox091
4. Louis DN. The next step in brain tumor classification: “let us now praise famous men”… or molecules? Acta Neuropathol. 2012;124(6):761-762. doi:10.1007/s00401-012-1067-4
5. Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget. 2015;6(30):30295.
6. Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679-693. doi:10. 1007/s00401-015-1409-0
7. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
8. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. doi:10.1093/neuonc/noab106
9. Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020;22(4):515-523. doi:10.1093/neuonc/noz200
10. Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2022; 128(1):47-58. doi:10.1002/cncr.33918
11. Van den Bent MJ, Geurts M, French PJ, et al. Primary brain tumours in adults. Lancet. 2023;402(10412):1564-1579. doi:10.1016/S0140-6736(23) 01054-1
12. Ferlay JE, Lam F. Global cancer observatory: cancer today (Version 1.0). International Agency for Research on Cancer [Internet]. 2024. https://gco.iarc.who.int/today
13. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10. 3322/caac.21660
14. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. doi:10.1002/ijc.33588
15. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1-iv62. doi: 10.1093/neuonc/nov189
16. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(12 Suppl 2):iv1-iv99. doi:10. 1093/neuonc/noad149
17. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012; 14(11):1316-1324. doi:10.1093/neuonc/nos208
18. Mack EE, Wilson CB. Meningiomas induced by high-dose cranial irradiation. J Neurosurg. 1993;79(1):28-31. doi:10.3171/jns.1993.79.1.0028
19. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896-913. doi:10.1093/neuonc/nou087
20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, World Health Organization (WHO) classification ot tumours of the central nervous system, 3rd edition, International Agency for Research on Cancer. Lyon. 2007.
21. Network TC. Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2013; 494(7438):506. doi:10.1038/nature11903
22. Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. Acta Neurochir. 2022;164(9):2453-2464. doi:10.1007/s00701-022-05301-y
23. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010;120(5): 567-584. doi:10.1007/s00401-010-0736-4
24. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489. doi:10.1093/jnen/64.6.479
25. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118(3):401-405. doi:10.1007/s00401-009-0550-z
26. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108. doi:10.1007/s00401-005-0991-y
27. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007; 131(2):242-251. doi:10.5858/2007-131-242-CAOQLA
28. Van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-350. doi:10.1200/JCO.2012.43.2229
29. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343. doi:10.1200/JCO.2012.43.2674
30. Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res. 2002;8(1):196-201.
31. Li L, Dutra A, Pak E, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009;11(1):9-21. doi:10.1215/15228517-2008-081
32. Park YW, Vollmuth P, Foltyn-Dumitru M, et al. The 2021 WHO classification for gliomas and implications on imaging diagnosis: part 1—Key points of the fifth edition and summary of imaging findings on adult-type diffuse gliomas. J Magn Reson Imaging. 2023;58(3):677-689. doi:10.1002/jmri.28743
33. Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4):e13062. doi:10.1111/bpa.13062
34. Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18):5146-5157. doi:10.1158/1078-0432.CCR-13-0017
35. Prayson RA. Neuropathology. In: Foundations in diagnostic pathology. Philadelphia, PA: Elsevier Churchill Livingstone; 2007:160-309.
36. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892-6899. doi:10. 1158/0008-5472.CAN-04-1337
37. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772. doi:10.1158/1078-0432.CCR-12-3002
38. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022;24(Suppl 5):v1-v95. doi:10.1093/neuonc/noac202
39. Narita Y, Shibui S; Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical Society. Trends and outcomes in the treatment of gliomas based on data during 2001-2004 from the brain tumor registry of Japan. Neurol Med Chir (Tokyo). 2015;55(Suppl 1):286-295.
40. Bilgin E, Duman BB, Altintas S, Cil T, Gezercan Y, Okten AI. Predictors of survival in Turkish patients with primary glioblastoma. Turk Neurosurg. 2021;31(4):641-653. doi:10.5137/1019-5149.JTN.33332-20.3
41. Sucuoğlu İşleyen Z, Seçmeler Ş, Sakin A, et al. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study. BMC Cancer. 2026;26(1):347. doi:10.1186/s12885-026-15725-9
42. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10. 3322/caac.21834
43. Iuchi T, Sugiyama T, Ohira M, et al. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 2018;35(2):71-80. doi:10.1007/s10014-018-0309-0
44. Brodbelt A, Greenberg D, Winters T, et al. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015;51(4):533-542. doi:10.1016/j.ejca.2014.12.014
45. Tumturk A, Ozdemir MA, Per H, et al. Pediatric central nervous system tumors in the first 3 years of life: pre-operative mean platelet volume, neutrophil/lymphocyte count ratio, and white blood cell count correlate with the presence of a central nervous system tumor. Childs Nerv Syst. 2017;33(2):233-238. doi:10.1007/s00381-016-3301-1
46. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
47. Jones DT, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci. 2012;69(11):1799-1811. doi:10.1007/s00018-011-0898-9
48. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108(1): 49-56. doi:10.1007/s00401-004-0861-z
49. Kemerdere R, Yuksel O, Kacira T, et al. Low-grade temporal gliomas: surgical strategy and long-term seizure outcome. Clin Neurol Neurosurg. 2014;126:196-200. doi:10.1016/j.clineuro.2014.09.007
50. Tabouret E, Nguyen AT, Dehais C, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 2016;132(4):625-634. doi:10.1007/s00401-016-1611-8
51. Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4):e13062. doi:10.1111/bpa.13062
Article available in :
Volume 4, Issue 2, 2026
Page : 31-39
https://doi.org/10.51271/JCHOR-0079
Article Information
Received : 11 Şub 2026
Accepted : 12 Nis 2026
Published : 18 May 2026
Corresponding Author :

Nilay Bakoglu Malinowski: Department of Pathology, Faculty of Medicine, İstanbul Medipol University, İstanbul, Turkiye

[email protected]
Citation : Bakoğlu Malinowski N, Çakır E, Saygın İ. Retrospective analysis of glial tumors in light of the 2016 WHO classification of central nervous system tumours diagnosed at a single center between 2005 and 2016. J Curr Hematol Oncol Res. 2026;4(2):31-39. doi:10.51271/JCHOR-0079

Read: 171
Download : 89
Cited: 0
_Footer